363 related articles for article (PubMed ID: 32194562)
1. Selective Janus Kinase 1 Inhibition Is a Promising Therapeutic Approach for Lupus Erythematosus Skin Lesions.
Fetter T; Smith P; Guel T; Braegelmann C; Bieber T; Wenzel J
Front Immunol; 2020; 11():344. PubMed ID: 32194562
[TBL] [Abstract][Full Text] [Related]
2. Spleen tyrosine kinase (SYK) is a potential target for the treatment of cutaneous lupus erythematosus patients.
Braegelmann C; Hölzel M; Ludbrook V; Dickson M; Turan N; Ferring-Schmitt S; Sternberg S; Bieber T; Kuhn A; Wenzel J
Exp Dermatol; 2016 May; 25(5):375-9. PubMed ID: 26910509
[TBL] [Abstract][Full Text] [Related]
3. Immunostimulatory Endogenous Nucleic Acids Drive the Lesional Inflammation in Cutaneous Lupus Erythematosus.
Scholtissek B; Zahn S; Maier J; Klaeschen S; Braegelmann C; Hoelzel M; Bieber T; Barchet W; Wenzel J
J Invest Dermatol; 2017 Jul; 137(7):1484-1492. PubMed ID: 28351661
[TBL] [Abstract][Full Text] [Related]
4. JAK inhibitor ruxolitinib inhibits the expression of cytokines characteristic of cutaneous lupus erythematosus.
Klaeschen AS; Wolf D; Brossart P; Bieber T; Wenzel J
Exp Dermatol; 2017 Aug; 26(8):728-730. PubMed ID: 27892610
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of JAK1/2 inhibition in the treatment of chilblain lupus due to TREX1 deficiency.
Briand C; Frémond ML; Bessis D; Carbasse A; Rice GI; Bondet V; Duffy D; Chatenoud L; Blanche S; Crow YJ; Neven B
Ann Rheum Dis; 2019 Mar; 78(3):431-433. PubMed ID: 30282666
[No Abstract] [Full Text] [Related]
6. NKG2D and its ligands as cytotoxic factors in cutaneous lupus erythematosus.
Vorwerk G; Zahn S; Bieber T; Wenzel J
Exp Dermatol; 2021 Jun; 30(6):847-852. PubMed ID: 33687107
[TBL] [Abstract][Full Text] [Related]
7. Preclinical characterization of itacitinib (INCB039110), a novel selective inhibitor of JAK1, for the treatment of inflammatory diseases.
Covington M; He X; Scuron M; Li J; Collins R; Juvekar A; Shin N; Favata M; Gallagher K; Sarah S; Xue CB; Peel M; Burke K; Oliver J; Fay B; Yao W; Huang T; Scherle P; Diamond S; Newton R; Zhang Y; Smith P
Eur J Pharmacol; 2020 Oct; 885():173505. PubMed ID: 32861662
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Clinical Response to Janus Kinase Inhibition in Patients With Familial Chilblain Lupus and TREX1 Mutation.
Zimmermann N; Wolf C; Schwenke R; Lüth A; Schmidt F; Engel K; Lee-Kirsch MA; Günther C
JAMA Dermatol; 2019 Mar; 155(3):342-346. PubMed ID: 30673078
[TBL] [Abstract][Full Text] [Related]
9. Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus.
Wenzel J; Wörenkämper E; Freutel S; Henze S; Haller O; Bieber T; Tüting T
J Pathol; 2005 Mar; 205(4):435-42. PubMed ID: 15685590
[TBL] [Abstract][Full Text] [Related]
10. Interferon-α stimulates TRAIL expression in human keratinocytes and peripheral blood mononuclear cells: implications for the pathogenesis of cutaneous lupus erythematosus.
Zahn S; Rehkämper C; Ferring-Schmitt S; Bieber T; Tüting T; Wenzel J
Br J Dermatol; 2011 Nov; 165(5):1118-23. PubMed ID: 21711324
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous Lupus Erythematosus: An Update on Pathogenesis and Future Therapeutic Directions.
Niebel D; de Vos L; Fetter T; Brägelmann C; Wenzel J
Am J Clin Dermatol; 2023 Jul; 24(4):521-540. PubMed ID: 37140884
[TBL] [Abstract][Full Text] [Related]
12. High expression of B lymphocyte stimulator in lesional keratinocytes of patients with cutaneous lupus erythematosus.
Wenzel J; Landmann A; Vorwerk G; Kuhn A
Exp Dermatol; 2018 Jan; 27(1):95-97. PubMed ID: 28833566
[TBL] [Abstract][Full Text] [Related]
13. JAK3 as an Emerging Target for Topical Treatment of Inflammatory Skin Diseases.
Alves de Medeiros AK; Speeckaert R; Desmet E; Van Gele M; De Schepper S; Lambert J
PLoS One; 2016; 11(10):e0164080. PubMed ID: 27711196
[TBL] [Abstract][Full Text] [Related]
14. Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata.
Dai Z; Chen J; Chang Y; Christiano AM
JCI Insight; 2021 Apr; 6(7):. PubMed ID: 33830087
[TBL] [Abstract][Full Text] [Related]
15. B Cell Signatures Distinguish Cutaneous Lupus Erythematosus Subtypes and the Presence of Systemic Disease Activity.
Abernathy-Close L; Lazar S; Stannard J; Tsoi LC; Eddy S; Rizvi SM; Yee CM; Myers EM; Namas R; Lowe L; Reed TJ; Wen F; Gudjonsson JE; Kahlenberg JM; Berthier CC
Front Immunol; 2021; 12():775353. PubMed ID: 34868043
[TBL] [Abstract][Full Text] [Related]
16. Photosensitivity and type I IFN responses in cutaneous lupus are driven by epidermal-derived interferon kappa.
Sarkar MK; Hile GA; Tsoi LC; Xing X; Liu J; Liang Y; Berthier CC; Swindell WR; Patrick MT; Shao S; Tsou PS; Uppala R; Beamer MA; Srivastava A; Bielas SL; Harms PW; Getsios S; Elder JT; Voorhees JJ; Gudjonsson JE; Kahlenberg JM
Ann Rheum Dis; 2018 Nov; 77(11):1653-1664. PubMed ID: 30021804
[TBL] [Abstract][Full Text] [Related]
17. Immunologic and genetic considerations of cutaneous lupus erythematosus: a comprehensive review.
Yu C; Chang C; Zhang J
J Autoimmun; 2013 Mar; 41():34-45. PubMed ID: 23380467
[TBL] [Abstract][Full Text] [Related]
18. Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-cell Therapy.
Huarte E; O'Connor RS; Peel MT; Nunez-Cruz S; Leferovich J; Juvekar A; Yang YO; Truong L; Huang T; Naim A; Milone MC; Smith PA
Clin Cancer Res; 2020 Dec; 26(23):6299-6309. PubMed ID: 32998963
[TBL] [Abstract][Full Text] [Related]
19. Nano-encapsulated anandamide reduces inflammatory cytokines in vitro and lesion severity in a murine model of cutaneous lupus erythematosus.
McCormick ET; Draganski A; Chalmers S; Zahn J; Garcia S; Nussbaum D; Friedman A; Putterman C; Friedman J
Exp Dermatol; 2023 Dec; 32(12):2072-2083. PubMed ID: 37726950
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous lupus erythematosus: The impact of self-amplifying innate and adaptive immune responses and future prospects of targeted therapies.
Fetter T; Wenzel J
Exp Dermatol; 2020 Nov; 29(11):1123-1132. PubMed ID: 32633821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
